Cns Pharmaceuticals Ownership
| CNSP Stock | USD 1.28 0.01 0.78% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 382.2 K | Current Value 2.7 M | Avarage Shares Outstanding 21.3 M | Quarterly Volatility 21.4 M |
Cns Stock Ownership Analysis
The company has price-to-book (P/B) ratio of 0.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cns Pharmaceuticals recorded a loss per share of 924.6. The entity had not issued any dividends in recent years. The firm had 1:50 split on the 21st of February 2025. CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company was incorporated in 2017 and is based in Houston, Texas. Cns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. For more info on Cns Pharmaceuticals please contact JD Esq at 800 946 9185 or go to https://www.cnspharma.com.Besides selling stocks to institutional investors, Cns Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cns Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cns Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Cns Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Cns Pharmaceuticals are currently held by insiders. Unlike Cns Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cns Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Cns Pharmaceuticals' insider trades
Cns Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cns Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cns Pharmaceuticals backward and forwards among themselves. Cns Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Cns Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-12-31 | 440 | Barrett & Company, Inc. | 2025-03-31 | 100.0 | Sbi Securities Co Ltd | 2025-03-31 | 15.0 | Wells Fargo & Co | 2024-12-31 | 4.0 | Goldman Sachs Group Inc | 2025-03-31 | 0.0 | Tower Research Capital Llc | 2024-12-31 | 0.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Aspire Private Capital, Llc | 2024-12-31 | 0.0 | Synergy Investment Management, Llc | 2025-03-31 | 0.0 | Jane Street Group Llc | 2024-12-31 | 419.7 K | Geode Capital Management, Llc | 2024-12-31 | 387.1 K |
Cns Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cns Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cns Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cns Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cns Pharmaceuticals Outstanding Bonds
Cns Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cns Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cns bonds can be classified according to their maturity, which is the date when Cns Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| CNO 175 07 OCT 26 Corp BondUS18977W2A75 | View | |
| CNO 265 06 JAN 29 Corp BondUS18977W2C32 | View | |
| US189754AC88 Corp BondUS189754AC88 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| NOVHOL 6625 15 APR 29 Corp BondUS18972EAA38 | View | |
| NOVHOL 875 15 APR 30 Corp BondUS18972EAB11 | View |
Pair Trading with Cns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Cns Stock
| 0.77 | DYAI | Dyadic International | PairCorr |
| 0.7 | VRCA | Verrica Pharmaceuticals | PairCorr |
| 0.77 | VRDN | Viridian Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to Cns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cns Pharmaceuticals to buy it.
The correlation of Cns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Cns Stock Analysis
When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.